This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
167
Investigational drug
Matching placebo
FALCON Research Site
Birmingham, Alabama, United States
FALCON Research Site
Homewood, Alabama, United States
Percent Change in Body Weight
Percent change (%) in body weight from baseline to Week 12
Time frame: 12 weeks
Change in Body Weight
Change in body weight (kg) from baseline to Week 12
Time frame: 12 weeks
≥ 5% Weight Loss
Proportion of participants achieving ≥ 5% weight loss
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
FALCON Research Site
Tucson, Arizona, United States
FALCON Research Site
Spring Valley, California, United States
FALCON Research Site
Port Orange, Florida, United States
FALCON Research Site
Louisville, Kentucky, United States
FALCON Research Site
Marrero, Louisiana, United States
FALCON Research Site
Boston, Massachusetts, United States
FALCON Research Site
Rochester, Minnesota, United States
FALCON Research Site
City of Saint Peters, Missouri, United States
...and 7 more locations